Opinion

Video

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies

Author(s):

Pedro Barata, MD, MSc, FACP

Key Takeaways

  • Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations.
  • Safety profiles of PARP inhibitors were consistent with known effects, with manageable adverse events observed.
SHOW MORE

Panelists discuss how the PROfound trial (NCT02987543) demonstrated the efficacy and safety of olaparib monotherapy in metastatic prostate cancer patients with homologous recombination repair gene alterations, highlighting its potential as a targeted treatment option and its impact on the landscape of precision medicine in prostate cancer management.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video Content above is prompted by the following:

      • Discuss efficacy and safety findings from monotherapy trials PARP inhibitors in metastatic prostate cancer harboring homologous recombination repair gene alterations.
        • PROfound trial (olaparib), NCT02987543

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Topline Data From the BOND-003 Trial in NMIBC
      Topline Data From the BOND-003 Trial in NMIBC
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      1 expert is featured in this series.
      Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
      1 expert is featured in this series.
      A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
      3 experts are featured in this series.
      Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      1 expert is featured in this series.
      Remaining unmet needs in diverse populations with mHSPC
      Related Content
      FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
      June 20th 2025

      FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

      Hannah Clarke
      The phase 1 study is set to begin later this year.
      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
      June 19th 2025

      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

      Amy M. Pearlman, MD
      The conversation covers practical, case-based strategies for counseling MSM patients.
      Real-world studies compare overall survival between ARPIs in mCSPC
      June 19th 2025

      Real-world studies compare overall survival between ARPIs in mCSPC

      Mehmet Asim Bilen, MD Hannah Clarke
      "Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
      June 2nd 2025

      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

      Amy M. Pearlman, MD
      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
      June 17th 2025

      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

      Hannah Clarke
      ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
      FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
      June 17th 2025

      FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

      Hannah Clarke
      Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
      © 2025 MJH Life Sciences

      All rights reserved.